JLPC(SH:600513) Zheng Quan Zhi Xing·2025-08-26 16:35Core Viewpoint - Jiangsu Lianhuan Pharmaceutical Co., Ltd. (hereinafter referred to as "the Company" or "Lianhuan Pharmaceutical") is set to issue technology innovation bonds with a guarantee from its controlling shareholder, Jiangsu Lianhuan Pharmaceutical Group Co., Ltd. (hereinafter referred to as "Lianhuan Group"), amounting to a maximum of RMB 500 million, without any guarantee fees or counter-guarantees required from the Company [1][2][4]. Transaction Overview - The Company plans to register and issue RMB 500 million in technology innovation bonds, with a maturity of no more than 3 years, supported by a joint liability guarantee from Lianhuan Group [1][4]. - The transaction is classified as a related party transaction but does not constitute a major asset restructuring as defined by the relevant regulations [2][4]. Related Party Information - Lianhuan Group holds a 39.90% stake in the Company and is its controlling shareholder, with its actual controller being the State-owned Assets Supervision and Administration Commission of the People's Government of Yangzhou [2]. Financial Data - As of March 31, 2025, the Company reported total assets of RMB 894,081.58 million and total liabilities of RMB 469,162.50 million, indicating a significant increase from the previous year [3]. - The Company’s revenue for the year was RMB 560,339.27 million, with a net profit of RMB 34,552.69 million [4]. Guarantee Details - The expected guarantee amount from Lianhuan Group for the financing is RMB 500 million, with cumulative guarantees provided to the Company amounting to RMB 140 million, all of which are current and without overdue situations [4][5]. Impact of the Transaction - The guarantee from Lianhuan Group is intended to facilitate the smooth issuance of the technology innovation bonds, supporting the Company's operational activities without harming the interests of the Company or its minority shareholders [4][5]. Approval Process - The transaction has been approved by the Company’s board and supervisory committee, with related directors and supervisors abstaining from voting to ensure compliance with legal regulations [5].